{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032517","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.236030+00:00","generated_at":"2026-05-31T09:07:16.061267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MangoRx reports H1 2024 revenue up 56% YoY to $377K; shareholders' equity jumps 1,685% to $13.8M","bullets":["Revenue $377,258 for six months ended June 30, 2024, up 55.92% from $241,959 YoY; gross profit $217,190 (+50.48%).","Shareholders' equity increased to $13,829,445 vs $774,754 at Dec 31, 2023 (+1,685%), largely due to Intramont patent portfolio acquisition in April 2024.","Company plans to launch compounded ODT GLP-1 inhibitors (Semaglutide/Tirzepatide) for weight loss and hormone therapy MOJO (Enclomiphene/pregnenolone).","CEO highlights launch of DEA-approved telemedicine operating system."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032517","json":"https://secwatch.observer/filing/0001493152-24-032517.json","markdown":"https://secwatch.observer/filing/0001493152-24-032517.md","text":"https://secwatch.observer/filing/0001493152-24-032517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224032517/0001493152-24-032517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315224032517/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:07:16.061267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}